FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDimerix Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
DXB.AX
Dimerix Limited Stock AnalysisComprehensive stock analysis for Dimerix Limited (DXB.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDXB.AX
DXB.AX
Dimerix Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
DXB.AX
  1. Home
  2. Stocks
  3. Dimerix Limited

Dimerix Limited

🇦🇺DXB.AX•ASX

Dimerix Limited

🇦🇺DXB.AX•ASX

Your view on DXB.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Dimerix Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Nina Webster
Headquarters
425 Smith Street, Fitzroy, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Nina Webster
Headquarters
425 Smith Street, Fitzroy, VIC, AU
Description

Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient.

The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19.

DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD).

The company's corporate headquarters are located in Fitzroy, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Dimerix Limited. Starting points for Dimerix Limited: EPS -AUD 0.05, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Dimerix Limited. Dimerix Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Dimerix Limited. Trailing twelve-month EPS for Dimerix Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00−AUD 0.04−AUD 0.03
Lowest estimateAUD 0.00−AUD 0.04−AUD 0.03
Highest estimateAUD 0.00−AUD 0.04−AUD 0.03
Number of analysts011
A year ago—−AUD 0.05—
Growth vs a year ago—+23.5%—

Revenue estimates

TotalThis quarterDec 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 2.74MAUD 9.10MAUD 21.50M
Lowest estimateAUD 2.74MAUD 9.10MAUD 21.50M
Highest estimateAUD 2.74MAUD 9.10MAUD 21.50M
Number of analysts111
A year ago—AUD 4.35M—
Growth vs a year ago—+109.2%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Dimerix Limited. Dimerix Limited has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DXB.AX19 companies
Compare DXB.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
ATH.AXAlterity Therapeutics LimitedHealthcareBiotechnology—
ATX.AXAmplia Therapeutics LimitedHealthcareBiotechnology—
ILA.AXIsland Pharmaceuticals LimitedHealthcareBiotechnology—
NOX.AXNoxopharm LimitedHealthcareBiotechnology—
NYR.AXNyrada Inc.HealthcareBiotechnology—
PTX.AXPrescient Therapeutics LimitedHealthcareBiotechnology—
RAC.AXRace Oncology LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
PULMPulmatrix, Inc.HealthcareNASDAQ$4.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
PYC.AXPYC Therapeutics LimitedHealthcareASX—
OBXObsidian Therapeutics Inc.HealthcareNASDAQ$12.7M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Dimerix Limited.

DXB.AX AnalysisWeak
Past
1
Growth
5
Health
1
Profit
1
Value
1